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Abstract: Angiogenesis is an important process in cancer growth and metastasis. During the 
tumor angiogenic process, endothelial cells express various cell surface receptors which can be 
utilized for molecular imaging and targeted drug delivery. One such protein receptor of interest 
is the integrin αvβ3. Our group is involved in the development of molecular imaging probes 
and drug delivery systems targeting αvβ3. Based on extensive lead optimization study with the 
integrin antagonist compounds, we have developed a new generation of integrin αvβ3 compound 
(IA) which has superior binding afﬁ  nity to αvβ3. Utilizing this IA as a targeting agent, we have 
developed a novel integrin-targeted nanoparticle (ITNP) system for targeted drug delivery and 
imaging of cancer angiogenesis. When multiple copies of the IA were conjugated onto the 
nanoparticle surface, strong and selective binding to the integrin αvβ3 was observed. These 
ITNPs also were rapidly taken up by cells that express αvβ3. The ITNPs accumulated in the 
angiogenic vessels, after systemic administration in a murine squamous cell carcinoma model. 
This novel intergrin targeted ITNP platform will likely have an application in targeted delivery 
of drugs and genes in vivo and can also be used for molecular imaging.
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Introduction
Angiogenesis is required for cancer growth and is highly associated with cancer 
metastasis. Integrin αvβ3 is a cell-surface receptor protein that is upregulated in 
various pathological conditions including osteoporosis, rheumatoid arthritis, macular 
degeneration as well as cancer angiogenesis (Eliceiri and Cheresh 2000; Ruoslahti 
2002). Integrin αvβ3 is a widely recognized target for the development of molecular 
probes for imaging angiogenesis and for cancer therapy. Integrin αvβ3 antagonists 
induce apoptosis on activated endothelial cells and also αvβ3 positive tumor cells 
(Taga et al 2002). Vitaxin, an antibody for αvβ3 and cilengitide, a cyclic peptide 
(Tucker 2006) both block αvβ3 and are in clinical trials as antiangiogenic agents 
in patients with various tumors (Gutheil et al 2000; Raguse et al 2004). A number 
of research groups have developed αvβ3 targeted nanomaterials for imaging and 
therapy (Winter et al 2003; Lim et al 2006). A paramagnetic polymerized liposomal 
nanoparticle was developed by attaching the αvβ3 antibody LM609 onto the surface 
of the nanoparticle (Storrs et al 1995), and this polymerized nanoparticle showed 
good tumor accumulation in the VX2 rabbit tumor model (Sipkins et al 1998). 
Similar targeted polymerized liposomes have also been developed for targeted gene 
delivery, in which the targeting agent is a small molecule integrin antagonist instead 
of an antibody (Hood et al 2002). These particles also demonstrated angiogenesis 
targeting in murine tumor models. We have developed a novel integrin antagonist 
which has more than 20 times better binding afﬁ  nity to αvβ3 compared to the one 
that was used by Hood et al (Duggan et al 2000; Burnett et al 2005). Here we report 
a novel ITNP system that has this high afﬁ  nity integrin antagonist compound as the International Journal of Nanomedicine 2007:2(3) 480
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targeting agent and the subsequent studies involving the in 
vivo tumor angiogenesis targeting.
Methods and materials
Synthesis of targeting lipid BisT-PE-
EDTA-IA (Scheme 1)
Ethylenediaminetetraacetic acid dianhydride (EDTA-
dianhydride, 135 mg, 525 μmoles) was dissolved 
in a dry 3-neck flask, under a positive pressure of 
argon, in pyridine (20 mL). To this solution was 
added 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-
phosphoethanolamine (436 mg, 500 μmoles) in methylene 
chloride (5 mL) drop wise using a syringe pump at the rate 
of 2.5 mL per hour. The starting material had completely 
disappeared after two hours stirring, as observed by thin 
layer chromatography. To this reaction was added the 
integrin antagonist compound (271mg, 550 μmoles) and 
allowed to stir for 72 hours. The reaction mixture was 
partitioned between methylene chloride (100 mL) and 
water (20 mL). The organic layer was separated and washed 
with brine (10 mL) and then dried over anhydrous sodium 
sulfate. The solution was ﬁ  ltered to remove sodium sulfate 
and the solvent was then removed by spin evaporation and 
the residue was dried under high vacuum over night. The 
crude product was puriﬁ  ed by ﬂ  ash chromatography using 
CHCl3/CH3OH/H2O/NH4OH (50/40/5/5) as the solvent to 
yield 102 mg of the desired product (yield = 13%). 1H NMR: 
(CDCl3:CD3OD 1:1, 300 MHz, δ ppm) 7.65 (2H, d, Ar-H), 
6.75 (2H, d, Ar-H), 0.65–1.05 (116H, overlapping peaks, 
2-CH3 54-CH2 and 2-CH), 0.8 (6H, s, CH3). MALDI-MS: 
M+H+ = 1585.842.
Synthesis of integrin-targeted 
nanoparticle (ITNP)
The ITNP consists of two lipids with encapsulated rhodamine-
B (Figure 1). The ﬁ  rst lipid is 1,2-bis(10,12-tricosadiynoyl)-
sn-glycero-3-phosphoethanolamine-ethylendiaminetetraacetic 
acid-integrin antagonist (BisT-PE-EDTA-IA) and the second 
lipid is the base lipid 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-
3-phosphocholine (BisT-PC) lipid. The BisT-PC lipid was 
purchased from Avanti Polar Lipids. The BisT-PE-EDTA-IA 
was synthesized from commercially available BisT-PE lipid 
as described above. Targeting lipid (BisT-PE-EDTA-IA) and 
the base lipid (BisT-PC, Avanti lipids) were dissolved in a 1:1 
mixture of chloroform and methanol and were spin-evaporated 
to make a thin ﬁ  lm. The ﬁ  lm was dried under high vacuum over 
night. This ﬁ  lm was hydrated with 10 mM ammonium chloride 
solution and was gently mixed. The suspension was subjected 
to 5 consecutive freeze-thaw cycles followed by 5 extrusion 
cycles through a 100 nm pore size polycarbonate membrane. 
The extruded particles were then dialyzed against a solution 
of rhodamine-B for 2 hours. The rhodamine-B loaded ITNPs 
Scheme 1 Schematic illustration for the chemical synthesis of targeting lipid (BisT-PE-EDTA-IA).
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were then dialyzed against 10 mM HEPES buffer pH 7.4 for 
3 hours. The dialyzed ITNPs were then ﬁ  ltered through 0.2 μ 
ﬁ  lter into a sterile vial. The size and zeta potential of the ITNPs 
were determined by dynamic light scattering. The ﬂ  uorescence 
spectra was recorded for the rhodamine.
Synthesis of control-NP
The control-NP consists of two lipids with encapsulated 
rhodamine-B. BisT-PE and BisT-PC lipids (Avanti Polar 
lipids) were dissolved in a 1:1 mixture of chloroform and 
methanol and were spin-evaporated to make a thin ﬁ  lm. The 
ﬁ  lm was dried under high vacuum over night. This ﬁ  lm was 
hydrated with 10 mM ammonium chloride solution and was 
gently mixed. The suspension was subjected to 5 consecutive 
freeze-thaw cycles followed by 5 extrusion cycles through 
a 100 nm pore size polycarbonate membrane. The extruded 
particles were then dialyzed against a solution of rhoda-
mine-B for 2 hours. The rhodamine-B loaded NPs were then 
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Figure 1 (a) Schematic diagram outlining the formation of the ITNPs by self-assembly of the appropriate lipids. The lipid with targeting agent (10 mole%) was combined 
with base lipid (90 mole%) in a solution of chloroform and methanol (1:1). The mean diameter of the ITNPs was 104.4 ± 3.3 nm, as determined by dynamic light scattering, 
and the zeta potential was approximately –43.8 mv. The ITNPs were stable for weeks without any observable changes in their physical and biological properties when for-
mulated for use in vivo. (b) Schematic diagram outlining the formation of the Control-NPs by self-assembly of the appropriate lipids. The mean diameter of the nanoparticle 
was 101.2 ± 2.4 nm, as determined by dynamic light scattering, and the zeta potential was approximately –32.6 mv.
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dialyzed against 10 mM HEPES buffer pH 7.4 for 3 hours. 
The dialyzed control-NPs were then ﬁ  ltered through 0.2 μ 
ﬁ  lter into a sterile vial. The size and zeta potential of the 
control-NPs were determined by dynamic light scattering.
Transmission electron microscopy
of the ITNPs
20 μl of the ITNP was added onto a carbon coated Formvar-
ﬁ  lm grid. The excess solution was removed by blotting and 
to this was added 1% phosphotungstic acid solution, pH 7.0. 
Excess phosphotungstic acid was removed by blotting. The 
grid surface was then air dried at room temperature. The grid 
was examined by an electron microscope operated at 75 kV 
(Hitachi H7000, Tokyo). Digital images were taken by a 
charge-coupled device camera (Gatan, Pleasanton, CA).
Binding afﬁ  nity assay
Purified integrin αvβ3 protein (Chemicon International, 
Temecula, CA) was applied to 96-well polystyrene microtiter 
plates at 0.1 μg/well. After overnight incubation at 4 °C the 
plates were washed, and then blocked with milk solution 
(KPL, Inc., Gaithersburg, MD) at room temperature for 2 h. 
The blocking buffer was removed, and the plates were in-
oculated in quadruplicate with ITNPs with a typical starting 
concentration of 1.25 μM. Serial dilutions were prepared in 
the 96-well plates using multichannel pipette. To each well 
was added biotinylated vitronectin solution (0.1 μg/well) 
as standard competitor. The plates were incubated at room 
temperature for 3 h, washed, and the bound vitronectin was 
detected using NeutrAvidin-HRP conjugate at 0.01 μg/well 
(Pierce, Rockford, IL) and LumiGlo chemiluminescent sub-
strate system (KPL, Inc., Gaithersburg, MD). The lumines-
cence was read using a Wallac Counter. The concentration 
of inhibitor producing 50% inhibition (IC50) of vitronectin 
binding to αvβ3 was calculated based on a curve ﬁ  tting model 
(Burnett et al 2005).
Cell uptake assay of the ITNPs
The M21 cells were cultured in RPMI 1640 medium (Bioﬂ  uids, 
Gaithersburg, MD) containing 10% fetal calf serum, 2 mM 
L-glutamine, and penicillin-streptomycin (50 IU ml–1 and 
50 μg ml–1, respectively, BioSource International; Rockville, 
MD) at 37 °C with 5% CO2, and were continuously maintained 
without over-conﬂ  uences. Before the experiment, the cells were 
passaged at 60%–70% conﬂ  uence two to three times and the 
cells were loaded to the glass culture chambers for the ITNPs 
cell uptake assay. Two hours before the cell tracking experiment 
cells were transferred into fresh medium to ensure the good 
condition of the cells. The ITNPs were added to the chamber 
yielding a ﬁ  nal concentration of 12 μmol/ml in the presence of 
10% fetal bovine serum culture medium for 5 min, 15 min, and 
30 min separately to obtain time course of the uptake of ITNPs 
into the cells. At different time points, the cells in the culture 
chamber were washed and ﬁ  xed with 4% Paraformaldehyde-
phosphate buffered saline for 20 minutes at RT. After ﬁ  xing, 
the cells were washed again and counterstained with a solution 
of 4′-6-Diamidino-2-phenylindole (DAPI) and observed by the 
Fluorescence microscopy to obtain the cellular distribution of 
the ITNPs at different time points.
In vivo/ex vivo studies
A SCC 7, murine squamous cell carcinoma model was used 
for the in vivo studies. The cells were cultured in RPMI 1640 
medium (Bioﬂ  uids, Gaithersburg, MD) containing 10% fetal 
calf serum, 2 mM L-glutamine, and penicillin-streptomycin 
(50 IU ml–1 and 50 μg ml–1, respectively, BioSource Inter-
national, Rockville, MD) at 37 °C with 5% CO2. The cells 
were pre-tested as mycoplasm negative (Research Animal 
Diagnostic Laboratory, University of Missouri, MO). Female 
C3H mice (6–9 weeks) were purchased from Charles River 
Laboratories (Gaithersburg, MD) to establish the squamous 
cell carcinoma mouse model. All animal work was performed 
according to an approved animal protocol and in compliance 
with the NIH Clinical Center Animal Care and Use Commit-
tee guidelines. Prior to the implantation of the tumor cells, the 
mice ﬂ  anks were shaved bilaterally and prepped with isopropyl 
alcohol. A suspension of SCC-7 cells (1 × 106 cells in 100 μl of 
PBS) was injected in each of the ﬂ  anks of each mouse with a 
27 G needle. On average, a tumor required 10 days to grow to 
half centimeter before the mice received the tail-vein injection 
of Rhodamine-B encapsulated ITNPs. Each mouse received 
100 μl of the ITNPs, and after 2 hrs the animal was euthanized. 
However, 15 minutes before euthanization, the mouse was 
injected with ﬂ  uorescein isothiocyante-lectin (FITC-lectin) 
by tail vein (Hunter et al 2006). The tumor was harvested for 
cryostat sections. The slides were counterstained with DAPI 
and the slides were examined with a Zeiss upright microscope 
using Rhodamine, FITC and DAPI ﬁ  lters to determine the 
biodistribution of the ITNPs within the cancerous tissues.
Results and discussion
Assembly of integrin-targeted ITNPs
For the construction of the integrin-targeted ITNPs, the criti-
cal step is the synthesis of targeting lipid BisT-PE-EDTA-IA 
as shown in Scheme 1. The IA was synthesized following 
previously published procedure (Burnett 2005). IA contains a International Journal of Nanomedicine 2007:2(3) 483
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primary amine functionality for the synthesis of the targeting 
lipid. EDTA-dianhydride has two reactive anhydrides and 
can be conjugated to two different amines one on each side 
by a single pot reaction. The IA and BisT-PE lipid each have 
one primary amine and by controlled reaction conditions we 
were able to conjugate them with EDTA-dianhydride. The 
crude product was puriﬁ  ed by column chromatography. The 
product was characterized by NMR and mass spectrometry. 
The ITNPs consists of a targeting lipid and a base lipid. These 
two lipid solutions were mixed together and a ﬁ  lm was made 
by evaporating the solvents. The ﬁ  lm was hydrated and after 
few freeze-thaw cycles, the ITNPs were prepared by extru-
sion through a polycarbonate membrane. Rhodamine-B was 
encapsulated inside the particle by ion-exchange process. The 
particles were puriﬁ  ed by dialysis and ﬁ  ltered through 0.2 
μm ﬁ  lter into a sterile vial. The mean diameter of the ITNP 
was 104.4 ± 3.3 nm by dynamic light scattering, the pH was 
7.40 and the zeta potential was –43.8 mV. An aliquot of the 
ITNPs when ﬁ  ltered through 10,000 MW cutoff spin ﬁ  lter, 
did not show any ﬂ  uorescence in the ﬁ  ltrate indicating that 
rhodamine-B was stably encapsulated inside the ITNPs and 
did not leak out. The ITNPs were stained with phosphotung-
stic acid at pH 7.0 and examined with Transmission electron 
microscopy (TEM). The ITNPs appeared as vesicles formed 
by a single large aqueous cavity surrounded by a thick mem-
brane (Figure 2). The TEM also conﬁ  rmed the size of ITNP 
was around 100 nm, in accordance with the measurement by 
dynamic light scattering.
Binding afﬁ  nity and cellular uptake
of the ITNPs
The binding afﬁ  nity of the targeted ITNPs to αvβ3 was tested 
by coating 96 well plates with αvβ3. This is a competitive 
inhibition assay, where the ability of the ITNPs to competi-
tively inhibit the binding of vitronectin to αvβ3. We found 
that ITNPs showed excellent binding afﬁ  nity to the integrin 
αvβ3 (9.2 nM) (Figure 3). The control nanoparticles did not 
bind to αvβ3 even at very high concentration in the integrin 
αvβ3 plate binding assay (data not shown) which is easy to 
understand that the bilayer lipids do not have a good bind-
ing afﬁ  nity to the αvβ3 protein. Since we did not observe the 
binding afﬁ  nity of non-targeted particles to the αvβ3 protein, 
therefore we speciﬁ  cally only observed ITNPs cell uptake 
and in vivo anagiogenesis targeting as following.
Cell uptake of the ITNPs
When ITNPs were incubated with the M21 cells, it was 
observed that the ITNPs were accumulated in the cells within 
minutes and major presented in the cytoplasm of the M21 
cells, as observed by ﬂ  uorescence microscopy (Figure 4). 
This quick accumulation possibly happens by receptor 
mediated endocytosis. The uptake of the ITNPs was further 
investigated by live cell imaging and has been disclosed 
(Zhang et al 2006).
Tumor angiogenesis targeting
The targeted ITNPs were tail vein injected into C3H mice 
bearing murine squamous cell carcinoma (SCC-7) tumors to 
determine the in vivo ability to selectively target angiogenic 
vessels. Fifteen minutes prior to euthanasia, the animal was 
tail vein injected with FITC-lectin, which allowed us to 
observe the functional angiogenic vessels (Hunter 2006) 
and correlate with the distribution of the ITNPs in the func-
tional angiogenic vessels. The ITNPs were visualized by 
ﬂ  uorescence microscopy in the tumor angiogenic vessels 
which overlapped with the FITC-lectin signal, clearly dem-
onstrating the angiogenesis speciﬁ  c targeting of these ITNPs 
(Figure 5). Some accumulation was also seen in various other 
tissues, such as liver and spleen and minimal accumulation 
was observed in the lung capillary vessels, which warrants 
further optimization of the ITNPs such as size, charge and 
lipid composition.
Conclusion
We have synthesized a novel integrin targeted rhodamine-B 
encapsulated ITNP. This ITNP binds to the integrin αvβ3 in 
Figure 2 Transmission electron microscopic image of integrin targeted 
nanoparticles.
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the in vitro assay. In vivo the ITNP targets the tumor angio-
genic vessels, specially localized within the endothelial cells. 
Further optimization of this ITNP is feasible by modifying the 
size, charge and lipid composition. Incorporation of a wide 
variety of payloads for multi-modality imaging (magnetic 
resonance imaging, Positron emission tomography and 
optical imaging) and/or therapy (cytotoxic agent, radionu-
clide, and anti vascular agents) is in progress.
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Figure 4 Cellular uptake of the ITNPs by M21 cells in vitro. The ITNPs were added to the chamber yielding a ﬁ  nal concentration of 12 μmol/ml. After 5, 15, and 30 minutes 
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Figure 5 Angiogenic vessel targeting by the ITNPs. A: SCC-7 Cell nucleus stained by DAPI, B: Functional angiogenic vessels stained by injected FITC-Lectin, C: angiogenic 
vessels targeting by ITNPs observed by Rhodamine, D: Merge signals of the ITNPs targeted vessels and functional angiogenic vessels labeled by Lectin, E: Merge signals of the 
ITNPs targeted vessels, functional angiogenic vessels labeled by Lectin, and cell nuclear staining by DAPI. (scale bar = 50 um).
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